1. Home
  2. WVE vs AG Comparison

WVE vs AG Comparison

Compare WVE & AG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WVE
  • AG
  • Stock Information
  • Founded
  • WVE 2012
  • AG 1979
  • Country
  • WVE Singapore
  • AG Canada
  • Employees
  • WVE N/A
  • AG N/A
  • Industry
  • WVE Biotechnology: Pharmaceutical Preparations
  • AG Precious Metals
  • Sector
  • WVE Health Care
  • AG Basic Materials
  • Exchange
  • WVE Nasdaq
  • AG Nasdaq
  • Market Cap
  • WVE 1.8B
  • AG 1.9B
  • IPO Year
  • WVE 2015
  • AG N/A
  • Fundamental
  • Price
  • WVE $11.13
  • AG $5.56
  • Analyst Decision
  • WVE Strong Buy
  • AG Buy
  • Analyst Count
  • WVE 10
  • AG 2
  • Target Price
  • WVE $21.60
  • AG $8.50
  • AVG Volume (30 Days)
  • WVE 734.1K
  • AG 19.6M
  • Earning Date
  • WVE 03-05-2025
  • AG 02-20-2025
  • Dividend Yield
  • WVE N/A
  • AG 0.32%
  • EPS Growth
  • WVE N/A
  • AG N/A
  • EPS
  • WVE N/A
  • AG N/A
  • Revenue
  • WVE $53,610,000.00
  • AG $560,604,000.00
  • Revenue This Year
  • WVE N/A
  • AG N/A
  • Revenue Next Year
  • WVE $48.58
  • AG $54.92
  • P/E Ratio
  • WVE N/A
  • AG N/A
  • Revenue Growth
  • WVE N/A
  • AG N/A
  • 52 Week Low
  • WVE $4.01
  • AG $4.29
  • 52 Week High
  • WVE $16.74
  • AG $8.44
  • Technical
  • Relative Strength Index (RSI)
  • WVE 44.53
  • AG 47.30
  • Support Level
  • WVE $10.79
  • AG $5.24
  • Resistance Level
  • WVE $11.78
  • AG $5.81
  • Average True Range (ATR)
  • WVE 0.69
  • AG 0.31
  • MACD
  • WVE 0.05
  • AG -0.01
  • Stochastic Oscillator
  • WVE 43.95
  • AG 31.19

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About AG First Majestic Silver Corp. (Canada)

First Majestic Silver Corp is engaged in the production, development, exploration, and acquisition of mineral properties with a focus on silver and gold production in North America. It owns three producing mines, in Mexico consisting of the San Dimas Silver/Gold Mine, the Santa Elena Silver/Gold Mine and the La Encantada Silver Mine.

Share on Social Networks: